Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.5M | $30.0M | $49.2M | $54.4M | $74.6M | $88.1M | $99.4M | $268.8M |
| Cost of revenue | $277 | $22.6M | $32.1M | $34.6M | $43.7M | $44.0M | $48.6M | $141.7M |
| Gross profit | $18.5M | $7.3M | $17.1M | $19.8M | $28.4M | $44.1M | $50.8M | $127.1M |
| Gross margin | 100.0% | 24.5% | 34.8% | 36.4% | 38.1% | 50.0% | 51.1% | 47.3% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$139.0K | −$22.4M | −$23.0M | −$20.5M | −$6.9M | $10.6M | $13.6M | −$1.0M |
| EBITDA | −$139.0K | −$48.4M | −$6.0M | −$15.1M | −$10.0M | $14.6M | $17.6M | −$10.5M |
| Net income | −$139.0K | −$57.5M | −$22.9M | −$33.7M | −$42.5M | −$25.5M | −$28.0M | −$53.3M |
| Net margin | -0.8% | -191.9% | -46.6% | -61.9% | -56.9% | -29.0% | -28.2% | -19.8% |
| EPS (diluted) | -0.22 | -0.71 | -0.24 | -0.27 | -0.33 | -0.19 | -0.16 | -0.09 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds GDNSF.
No tracked institution reports a position in GDNSF as of their last filing.
No one on the platform has traded GDNSF yet.
| $74M |
| — |
| HRPMFHerantis Pharma Oyj | $3.51 | +0.00% | $59M | — |
| INNPFINNOCAN PHARMA Corp | $1.70 | -10.53% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.6× sales vs its 1.5× historical median P/S.
Fair value ≈ $1.07 · price $0.44 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.